Kymera Therapeutics, Inc. KYMR 深 滬

BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target

BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $134 price target.

今天 00:20

Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment

Kymera Therapeutics stock gained on Thursday after the company revealed quick e...

06-25 23:48

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Monday. Shares of Apogee Therapeutics Inc (NASDAQ:APGE) rose sharply on Monday. AbbVie Inc. (NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics in a cash deal valued at approximately $10.9 bi...

06-23 00:08

Kymera Therapeutics COO Resigns, Transition Plan Implemented

An update from Kymera Therapeutics ( ($KYMR) ) is now available. Kymera Therape...

06-09 05:10

Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with

06-08 19:23

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

06-08 11:00

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. A live webcast and replay will be available on the company’s website. Kymera specializes in developing oral small molecule degraders for immunological diseases and is a pioneer in targeted protein degradation.

05-27 11:00

Kymera Therapeutics Announces Presentations On Results From KT-621 Clinical Trial At Annual Meetings May 13-16

Society for Investigative Dermatology (SID) 2026 Annual MeetingTitle: KT-621 Treatment Induces Rapid STAT6 Degradation and Modulation of Th2 Gene Transcripts in Atopic Dermatitis Lesional SkinType/Session: Oral

05-15 19:06

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Kymera Therapeutics announced positive Phase 1b clinical data for KT-621, an oral STAT6 degrader, in treating Type 2 inflammatory diseases like atopic dermatitis and asthma. Results showed significant STAT6 degradation, reduction of inflammatory biomarkers, and clinical improvements, with favorable safety profiles. KT-621 is currently in Phase 2b trials for atopic dermatitis and asthma, with data expected in mid-2027 and late 2027, respectively. ...

05-15 11:00

美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价

今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元

05-07 12:37